They have cash, so they have options. But it might complicate thing from an FDA approval standpoint. To me it seems that the only way to get a foot in the door quickly would be through Synlait supplying A2 Platinum. Then hopefully transition this business over to MVM over the longer term. The devil will be in the detail of the Synlait supply agreements and the FDA application, so who knows.
They have cash, so they have options. But it might complicate...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$7.74 |
Change
-0.065(0.83%) |
Mkt cap ! $5.611B | |||
| Open | High | Low | Value | Volume |
| $7.87 | $7.87 | $7.71 | $4.013M | 517.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 7767 | $7.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.74 | 4208 | 12 |
View Market Depth
| Last trade - 13.19pm 27/06/2025 (20 minute delay) ? |
| A2M (ASX) Chart |